Tenascin-C: as a diagnostic biomarker for rheumatic heart disease

Tenascin-C: as a diagnostic biomarker for rheumatic heart disease

Background Rheumatic fever is a long-term inflammatory disease that can happen if group A beta-hemolytic streptococci bacteria are not treated well enough. Rheumatic fever is recognized globally as the leading cause of heart disease in the pediatric population. This disease destroys the heart muscle...

Full description

Saved in:
Bibliographic Details
Published in:The Gazette of the Egyptian Paediatric Association Vol. 71; no. 1; pp. 61 - 6
Main Authors: Abo-Hashish, Maha M. A., Ahmed, Azza Mohamed, Hegazi, Mohammad Ali, Mosaad, Naglaa Abdel Rahman, Ibrahim, Mona Hammed, Salam, Nagwan Yehia Abdel
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-12-2023
Springer
Springer Nature B.V
SpringerOpen
Subjects:
Acute rheumatic fever
Analysis
Bacteria
C-reactive protein
Cardiovascular disease
Children
Chronic rheumatic heart disease
Diseases
Ethylenediaminetetraacetic acid
Females
Fibroblasts
Health aspects
Heart
Inflammatory diseases
Medical diagnosis
Medicine
Medicine & Public Health
Pediatric cardiology
Pediatrics
Rheumatic fever
Rheumatic heart disease
Serum tenascin-C
Egypt
Taiwan
Chronic rheumatic heart disease
Acute rheumatic fever
Serum tenascin-C
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Rheumatic fever is a long-term inflammatory disease that can happen if group A beta-hemolytic streptococci bacteria are not treated well enough. Rheumatic fever is recognized globally as the leading cause of heart disease in the pediatric population. This disease destroys the heart muscle, progressively deteriorating its structure and impairing the function of its valves over time. Aim The aim of this study is to determine the role of serum tenascin-C in the diagnosis of acute rheumatic fever and chronic rheumatic heart disease. Methods This case–control study involved a group of 60 Egyptian children. Among them, 20 were diagnosed with acute rheumatic fever, identified using the updated Jones criteria from 2015. Another 20 children, who were suffering from chronic rheumatic heart disease, were also act as a part of the study. The remaining 20 participants, healthy children carefully matched in age and sex, served as the control group. Results Serum tenascin-C level was significantly increased in acute rheumatic fever (ARF) and highly significantly increased in chronic rheumatic heart disease (CRHD) groups when compared with control group ( P  = 0.04, 0.01), respectively. There were highly significant difference between and within the studied groups regarding the mean of serum tenascin-C. Serum tenascin-C mean of ARF, CRHD, and control was 4.82 ± 18.7, 5.46 ± 1.6, and 3.78 ± 2.4, respectively, P  = 0.02. Level of serum tenascin-C was lower in cases with severe mitral valve insufficiency. No significant link was found between the level of serum tenascin-C and C-reactive protein (CRP), ESR, and ASO titer, with a P -value greater than 0.5. ROC curve for serum tenascin-C in ARF patients was area under the curve = 0.682 ( P  = 0.05) with optimal serum tenascin-C cut-off point (> 3.76 ng/ml); ROC curve for serum tenascin-C in CRHD patients was AUC  = 0.73 ( P  = 0.01) with cut-off point level (73.76 ng/ml). Conclusion Patients with ARF and CRHD have increased level of serum tenascin-C. Serum tenancin-C is superior in the diagnosis of ARF in comparison to CRP, ESR, and ASOT. Tenascin-C level can be used as a diagnostic marker for ARF and CRHD.
ISSN:2090-9942
1110-6638
2090-9942
DOI:10.1186/s43054-023-00208-4